Fiche publication
Date publication
novembre 2010
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BARBERI-HEYOB Muriel
,
Dr FROCHOT Céline
,
Dr VANDERESSE Régis
Tous les auteurs :
Verhille M, Couleaud P, Vanderesse R, Brault D, Barberi-Heyob M, Frochot C
Lien Pubmed
Résumé
Photodynamic therapy (PDT) is a cancer treatment modality involving the combination of light, a photosensitizer (PS) and molecular oxygen, which results in the production of cytotoxic reactive oxygen species (ROS). Singlet oxygen (O-1(2)) is one of the most important of these ROS. Because the lifetime and diffusion of O-1(2) is very limited, a controllable singlet oxygen generation with high selectivity and localization would lead to more efficient and reliable PDT. The lack of selective accumulation of the PS within tumour tissue is a major problem in PDT. Targeted PDT would offer the advantage to enhance photodynamic efficiency by directly targeting diseased cells or tissues. Many attempts have been made to either selectively deliver light to diseased tissues or increase the uptake of the photoactive compounds by the target cells. The review will survey the literature regarding the multi-level control of O-1(2) production for PDT applications. The mechanisms of ROS formation are described. The different strategies leading to targeted formation of O-1(2) are developed. Some active PDT agents have been based on energy transfer between PS by control of the aggregation/disaggregation. The concept of molecular beacon based on quenching-dequenching upon protease cleavage is capable of precise control of O-1(2) by responding to specific cancer-associated biomarkers.
Référence
Curr Med Chem. 2010;17(32):3925-43.
